Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms

Texto completo
Autor(es):
Mostrar menos -
Schmitt, Andrea ; Martins-de-Souza, Daniel ; Akbarian, Schahram ; Cassoli, Juliana S. ; Ehrenreich, Hannelore ; Fischer, Andre ; Fonteh, Alfred ; Gattaz, Wagner F. ; Gawlik, Michael ; Gerlach, Manfred ; Grunblatt, Edna ; Halene, Tobias ; Hasan, Alkomiet ; Hashimoto, Kenij ; Kim, Yong-Ku ; Kirchner, Sophie-Kathrin ; Kornhuber, Johannes ; Kraus, Theo F. J. ; Malchow, Berend ; Nascimento, Juliana M. ; Rossner, Moritz ; Schwarz, Markus ; Steiner, Johann ; Talib, Leda ; Thibaut, Florence ; Riederer, Peter ; Falkai, Peter ; Force, Members WFSBP Task
Número total de Autores: 28
Tipo de documento: Artigo Científico
Fonte: WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY; v. 18, n. 5, p. 330-356, 2017.
Citações Web of Science: 4
Resumo

Objectives: Despite progress in identifying molecular pathophysiological processes in schizophrenia, valid biomarkers are lacking for both the disease and treatment response. Methods: This comprehensive review summarises recent efforts to identify molecular mechanisms on the level of protein and gene expression and epigenetics, including DNA methylation, histone modifications and micro RNA expression. Furthermore, it summarises recent findings of alterations in lipid mediators and highlights inflammatory processes. The potential that this research will identify biomarkers of schizophrenia is discussed. Results: Recent studies have not identified clear biomarkers for schizophrenia. Although several molecular pathways have emerged as potential candidates for future research, a complete understanding of these metabolic pathways is required to reveal better treatment modalities for this disabling condition. Conclusions: Large longitudinal cohort studies are essential that pair a thorough phenotypic and clinical evaluation for example with gene expression and proteome analysis in blood at multiple time points. This approach might identify biomarkers that allow patients to be stratified according to treatment response and ideally also allow treatment response to be predicted. Improved knowledge of molecular pathways and epigenetic mechanisms, including their potential association with environmental influences, will facilitate the discovery of biomarkers that could ultimately be effective tools in clinical practice. (AU)

Processo FAPESP: 13/08711-3 - Desenvolvimento de um teste preditivo para medicação bem sucedida e compreensão das bases moleculares da esquizofrenia através da proteômica
Beneficiário:Daniel Martins-de-Souza
Linha de fomento: Auxílio à Pesquisa - Apoio a Jovens Pesquisadores
Processo FAPESP: 14/10068-4 - EMU concedido no processo 13/08711-3: espectrômetro de massas Waters SYNAPT G2-Si HDMs + nanoACQUITY UPLC
Beneficiário:Daniel Martins-de-Souza
Linha de fomento: Auxílio à Pesquisa - Programa Equipamentos Multiusuários
Processo FAPESP: 14/14881-1 - Compreensão da influência de componentes da via glicolítica na função dos oligodendrócitos: uma relação com os achados em esquizofrenia
Beneficiário:Juliana Silva Cassoli
Linha de fomento: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 14/21035-0 - Proteômica quantitativa de linhagens neurais e organóides cerebrais derivados de células tronco de pluripotência induzida de pacientes com esquizofrenia
Beneficiário:Juliana Minardi Nascimento
Linha de fomento: Bolsas no Brasil - Pós-Doutorado